Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]

Sun Young Yim; Sung Hwan Lee; Seung Woo Baek; Bohwa Sohn; Yun Seong Jeong; Sang Hee Kang; Kena Park; Hyewon Park; Sunyoung S. Lee; Ahmed O. Kaseb; Young Nyun Park; Sun Hee Leem; Michael A. Curran; Ji Hoon Kim; Ju Seog Lee

doi:10.3350/cmh.2024.0333e

Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]

Sun Young Yim
, Sung Hwan Lee
, Seung Woo Baek
, Bohwa Sohn
, Yun Seong Jeong
, Sang Hee Kang
, Kena Park
, Hyewon Park
, Sunyoung S. Lee
, Ahmed O. Kaseb
, Young Nyun Park
, Sun Hee Leem
, Michael A. Curran
, Ji Hoon Kim
, Ju Seog Lee

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

In the original publication of this paper, the second graph in Figure 4B was erroneously identical with fourth graph in Figure 4B and correct version is provided below. We apologize for any inconvenience that may have been caused. The original article has been corrected as of 27th February 2025.

Original language	English (US)
Pages (from-to)	669-670
Number of pages	2
Journal	Clinical and Molecular Hepatology
Volume	31
Issue number	2
DOIs	https://doi.org/10.3350/cmh.2024.0333e
State	Published - Apr 2025

ASJC Scopus subject areas

Hepatology
Molecular Biology

Access to Document

10.3350/cmh.2024.0333e

Cite this

Yim, S. Y., Lee, S. H., Baek, S. W., Sohn, B., Jeong, Y. S., Kang, S. H., Park, K., Park, H., Lee, S. S., Kaseb, A. O., Park, Y. N., Leem, S. H., Curran, M. A., Kim, J. H., & Lee, J. S. (2025). Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]. Clinical and Molecular Hepatology, 31(2), 669-670. https://doi.org/10.3350/cmh.2024.0333e

Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]. / Yim, Sun Young; Lee, Sung Hwan; Baek, Seung Woo et al.
In: Clinical and Molecular Hepatology, Vol. 31, No. 2, 04.2025, p. 669-670.

Research output: Contribution to journal › Comment/debate › peer-review

Yim, SY, Lee, SH, Baek, SW, Sohn, B, Jeong, YS, Kang, SH, Park, K, Park, H, Lee, SS , Kaseb, AO, Park, YN, Leem, SH, Curran, MA, Kim, JH & Lee, JS 2025, 'Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]', Clinical and Molecular Hepatology, vol. 31, no. 2, pp. 669-670. https://doi.org/10.3350/cmh.2024.0333e

@article{8a5f19206e034838adf2c34ec6956081,

title = "Erratum to {\textquoteleft}Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial{\textquoteright} [Clin Mol Hepatol 2024;30:807-823]",

abstract = "In the original publication of this paper, the second graph in Figure 4B was erroneously identical with fourth graph in Figure 4B and correct version is provided below. We apologize for any inconvenience that may have been caused. The original article has been corrected as of 27th February 2025.",

author = "Yim, \{Sun Young\} and Lee, \{Sung Hwan\} and Baek, \{Seung Woo\} and Bohwa Sohn and Jeong, \{Yun Seong\} and Kang, \{Sang Hee\} and Kena Park and Hyewon Park and Lee, \{Sunyoung S.\} and Kaseb, \{Ahmed O.\} and Park, \{Young Nyun\} and Leem, \{Sun Hee\} and Curran, \{Michael A.\} and Kim, \{Ji Hoon\} and Lee, \{Ju Seog\}",

note = "Publisher Copyright: {\textcopyright} 2025 by Korean Association for the Study of the Liver.",

year = "2025",

month = apr,

doi = "10.3350/cmh.2024.0333e",

language = "English (US)",

volume = "31",

pages = "669--670",

journal = "Clinical and Molecular Hepatology",

issn = "2287-2728",

publisher = "Korean Association for the Study of the Liver",

number = "2",

}

TY - JOUR

T1 - Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma

T2 - Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]

AU - Yim, Sun Young

AU - Lee, Sung Hwan

AU - Baek, Seung Woo

AU - Sohn, Bohwa

AU - Jeong, Yun Seong

AU - Kang, Sang Hee

AU - Park, Kena

AU - Park, Hyewon

AU - Lee, Sunyoung S.

AU - Kaseb, Ahmed O.

AU - Park, Young Nyun

AU - Leem, Sun Hee

AU - Curran, Michael A.

AU - Kim, Ji Hoon

AU - Lee, Ju Seog

PY - 2025/4

Y1 - 2025/4

N2 - In the original publication of this paper, the second graph in Figure 4B was erroneously identical with fourth graph in Figure 4B and correct version is provided below. We apologize for any inconvenience that may have been caused. The original article has been corrected as of 27th February 2025.

AB - In the original publication of this paper, the second graph in Figure 4B was erroneously identical with fourth graph in Figure 4B and correct version is provided below. We apologize for any inconvenience that may have been caused. The original article has been corrected as of 27th February 2025.

UR - https://www.scopus.com/pages/publications/105003005165

UR - https://www.scopus.com/pages/publications/105003005165#tab=citedBy

U2 - 10.3350/cmh.2024.0333e

DO - 10.3350/cmh.2024.0333e

M3 - Comment/debate

C2 - 40012401

AN - SCOPUS:105003005165

SN - 2287-2728

VL - 31

SP - 669

EP - 670

JO - Clinical and Molecular Hepatology

JF - Clinical and Molecular Hepatology

IS - 2

ER -

Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this